At Novo Nordisk we are committed to discover, create and co-create innovation to solve healthcare challenges for people living with diabetes, obesity, cardiovascular disease, NASH, chronic kidney disease, and blood and endocrine disorders. One way of doing this is through our open innovation initiatives such as rewarding LabCentral Golden Tickets.
The first Novo Nordisk-sponsored Golden Tickets were awarded in 2019 to life sciences companies Cellino Biotech, Inc. and Summation Bio. Listen to their stories.
